Nuvilex, an international biotech company providing cell and gene therapy solutions for the treatment of diseases, recently held three days of meetings set up to cement the company’s objectives, strategy, and plans for future research and development.
The meeting agenda called for heavy emphasis on the preparation for late-phase clinical trials of Nuvilex, which will use the recently acquired Cell-in-a-Box™ technology as part of the treatment for those suffering from advanced, inoperable pancreatic cancer. Nuvilex acquired the rights to this technology from SG Austria; the license for its use in diabetes was acquired by Nuvilex from Austrianova Singapore.
Also on the discussion table was the potential role that the live-cell encapsulation technology might play in developing treatments for diabetes, as well as in the development of treatments for diseases using active compounds derived from marijuana.
Meeting participants included the officers and board of directors of Nuvilex, as well as principals professor Walter H. Gunzburg, chairman and chief technical officer of SG Austria, and Dr. Brian Salmons, CEO and president of Austrianova Singapore.
Drs. Gunzburg and Salmons developed and brought to maturity the cellulose-based live-cell encapsulation technology that is the basis for Nuvilex’s research and development efforts. The doctors were also directly involved in the successful phase 1/2 clinical trials in advanced, inoperable pancreatic cancer already conducted using this technology.
Drs. Gunzburg and Salmons will continue to work closely with the company in projects that involve the use of this technology.
“These meetings were important and essential in cementing our plans for developing treatments for serious and deadly diseases like cancer and diabetes through the use of the cellulose-based live cell encapsulation technology,” Kenneth L Waggoner, Nuvilex’s CEO and president, stated in the news release. “In that vein, we are extremely grateful to Drs. Gunzburg and Salmons for traveling from Singapore to join us in them and for agreeing to work closely with us in our efforts to employ the technology that they have developed.”
For more information, visit www.nuvilex.com
Let us hear your thoughts below:
